US 12,274,703 B2
Compositions and methods of treatment for neurological disorders comprising a dementia
Sylvain Lengacher, Geneva (CH); Charles Finsterwald, Geneva (CH); and Pierre Magistretti, Geneva (CH)
Assigned to GLIAPHARM SA, Geneva (CH)
Filed by Gliapharm SA, Geneva (CH)
Filed on Aug. 24, 2021, as Appl. No. 17/409,834.
Application 17/409,834 is a continuation in part of application No. 16/955,811, abandoned, previously published as PCT/IB2018/060445, filed on Dec. 20, 2018.
Claims priority of provisional application 62/608,599, filed on Dec. 21, 2017.
Prior Publication US 2022/0040197 A1, Feb. 10, 2022
Int. Cl. A61K 31/517 (2006.01); A61K 31/13 (2006.01); A61K 31/27 (2006.01); A61K 31/445 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/5513 (2013.01) [A61K 31/13 (2013.01); A61K 31/27 (2013.01); A61K 31/445 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01)] 9 Claims
 
1. A method of treating a neurological disease, wherein said neurological disease is selected from the groups consisting of Alzheimer's disease and a subtype thereof, in a subject in need thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula II:

OG Complex Work Unit Chemistry
wherein:
RII′ is −H;
BII is cyclopentyl optionally substituted with one or more RBII,
XII′ is —NR*—, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, or imidazolidinyl, each optionally and independently substituted with one or more RXII′;
XII is an C1-C10 alkylenyl wherein optionally one or more carbon atoms are each independently replaced by O, —C(O)—, —NR*—, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl or imidazolidinyl, and wherein the alkylenyl or said piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl or imidazolidinyl is optionally and independently substituted with one or more RXII;
YII is pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, thiazolyl, pyrazolyl, triazolyl, oxazolyl, benzoxazolyl, or benzoisoxazolyl, each optionally and independently substituted with one or more RYII,
each R* is independently-H or optionally substituted C1-C6 alkyl;
each RBII is independently C1-C6 alkyl, C1-C6 haloalkyl, halo, or —CN;
each RXII′ is independently C1-C6 alkyl, C1-C6 haloalkyl, halo or —CN;
each RXII is independently C1-C6 alkyl, C1-C6 haloalkyl, halo, —CN, cycloalkyl, or —NR*2; and
each RYII is independently C1-C6 alkyl, C1-C6 haloalkyl, —O(C1-C6 alkyl), halo, or —CN.